Innoviva (NASDAQ:INVA)‘s stock had its “hold” rating reaffirmed by equities researchers at Stifel Nicolaus in a report released on Friday. They currently have a $17.00 target price on the biotechnology company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 10.17% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Cowen set a $16.00 price objective on shares of Innoviva and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, October 25th. BidaskClub upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Deutsche Bank initiated coverage on shares of Innoviva in a research report on Monday, November 20th. They issued a “hold” rating and a $13.00 price target on the stock. Finally, Robert W. Baird restated a “hold” rating and issued a $13.00 price target on shares of Innoviva in a research report on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.83.

Innoviva (NASDAQ:INVA) opened at $15.43 on Friday. Innoviva has a 12 month low of $10.87 and a 12 month high of $16.11. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of -2.59. The company has a market cap of $1,666.67, a P/E ratio of 13.30 and a beta of 2.52.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Innoviva had a net margin of 61.76% and a negative return on equity of 47.13%. The business had revenue of $69.52 million for the quarter, compared to analyst estimates of $67.41 million. During the same quarter last year, the business earned $0.22 earnings per share. The business’s revenue for the quarter was up 59.4% on a year-over-year basis. research analysts expect that Innoviva will post 2.01 EPS for the current fiscal year.

In other Innoviva news, insider Michael W. Aguiar sold 12,022 shares of Innoviva stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.13, for a total value of $157,848.86. Following the transaction, the insider now owns 980,907 shares in the company, valued at $12,879,308.91. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP George B. Abercrombie sold 5,215 shares of Innoviva stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.26, for a total transaction of $69,150.90. Following the completion of the transaction, the vice president now owns 263,866 shares in the company, valued at approximately $3,498,863.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,522 shares of company stock worth $429,985. 1.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Profund Advisors LLC grew its position in Innoviva by 8.8% in the second quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock worth $195,000 after buying an additional 1,227 shares during the last quarter. Voya Investment Management LLC grew its position in Innoviva by 10.1% during the 2nd quarter. Voya Investment Management LLC now owns 37,937 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 3,470 shares in the last quarter. Thrivent Financial For Lutherans grew its position in Innoviva by 8.0% during the 2nd quarter. Thrivent Financial For Lutherans now owns 47,090 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 3,500 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Innoviva by 37.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,005 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,569 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Innoviva by 1.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 348,340 shares of the biotechnology company’s stock worth $4,459,000 after purchasing an additional 3,863 shares in the last quarter. Hedge funds and other institutional investors own 74.17% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Innoviva (INVA) Receives Hold Rating from Stifel Nicolaus” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/innoviva-inva-receives-hold-rating-from-stifel-nicolaus/1859610.html.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Analyst Recommendations for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.